MetaADEDB 2.0 @ LMMD
Aminolevulinic Acid
(ZGXJTSGNIOSYLO-UHFFFAOYSA-N)
Structure
SMILES
NCC(=O)CCC(=O)O
Type(s)
Approved
ATC code(s)
L01XD04
Molecular Formula:
C5H9NO3
Molecular Weight:
131.130
Log P:
0.0793
Hydrogen Bond Acceptor:
4
Hydrogen Bond Donor:
2
TPSA:
80.39
CAS Number(s):
106-60-5
Synonym(s)
1.
Aminolevulinic Acid
2.
5-Aminolaevulinate
3.
5-Aminolevulinate
4.
Aminolevulinic Acid Hydrochloride
5.
Delta-Aminolevulinic Acid
6.
Levulan
7.
5 Aminolaevulinate
8.
5 Aminolevulinate
9.
Acid Hydrochloride, Aminolevulinic
10.
Acid, Aminolevulinic
11.
Acid, Delta-Aminolevulinic
12.
Delta Aminolevulinic Acid
13.
Hydrochloride, Aminolevulinic Acid
External Link(s)
MeSHD000622
PubChem Compound7048523
137
BindingDB50240386
ChEBI356416
17549
CHEMBLCHEMBL601
DrugBankDB00855
DrugCentral166
IUPHAR/BPS Guide to PHARMACOLOGY4784
KEGGcpd:C00430
dr:D07567
Therapeutic Target DatabaseD03GLH
D0Y7ZD
ZINC3782550
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 11US FAERS
2Application site erythemaFAERS: 10US FAERS
3PainFAERS: 5

View details

17100738
17501954
18158756
19785604
19925929
21083701
 		CTD
US FAERS
4Application site painFAERS: 4US FAERS
5ErythemaFAERS: 419785604
21083701		CTD
US FAERS
6HypersensitivityFAERS: 3US FAERS
7Therapy cessationFAERS: 3US FAERS
8Application site pustulesFAERS: 2US FAERS
9NauseaFAERS: 2US FAERS
10No adverse eventFAERS: 2US FAERS
11PhotophobiaFAERS: 2US FAERS
12Urinary tract infectionFAERS: 2US FAERS
13UrticariaFAERS: 2US FAERS
14Alanine Aminotransferase IncreasedFAERS: 1US FAERS
15AmnesiaFAERS: 1US FAERS
16Application site exfoliationFAERS: 1US FAERS
17Application site pruritusFAERS: 1US FAERS
18Application site rashFAERS: 1US FAERS
19Application site reactionFAERS: 1US FAERS
20Application site scabFAERS: 1US FAERS
21Application site scarFAERS: 1US FAERS
22Application site warmthFAERS: 1US FAERS
23Aspartate Aminotransferase IncreasedFAERS: 1US FAERS
24Atrial FibrillationFAERS: 1US FAERS
25Cerebral InfarctionFAERS: 1US FAERS
26Contraindicated product administeredFAERS: 1US FAERS
27Depressed Level of ConsciousnessFAERS: 1US FAERS
28EpilepsyFAERS: 1US FAERS
29Eye BurnsFAERS: 1US FAERS
30Eye irritationFAERS: 1US FAERS
31Feeling abnormalFAERS: 1US FAERS
32General physical health deteriorationFAERS: 1US FAERS
33HeadacheFAERS: 1US FAERS
34LymphadenopathyFAERS: 1US FAERS
35Malignant neoplasm progressionFAERS: 1US FAERS
36SuperinfectionFAERS: 1US FAERS
37VomitingFAERS: 1US FAERS
38treatment failureFAERS: 1US FAERS
39Ataxia750224CTD
40Catatonia750224CTD
41Dermatitis, Photoallergic18798755CTD
42Hypotension11371878CTD
43Mycosis Fungoides11281435CTD
44Necrosis9328146
12095508		CTD
45Neoplasms11078907CTD
46Precancerous Conditions11078907CTD
47Psoriasis11281435CTD
48Seizures750224
15532533		CTD
49Skin Abnormalities15490483CTD
50Tachycardia11371878CTD
51Tissue Adhesions12095508CTD
52Tyrosinemias18665889CTD
53Vulvodynia17847765CTD
54Warts17100738CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120269

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.